SOURCE: Celmatix

Celmatix

October 22, 2014 15:45 ET

Celmatix Presents Study at the ASRM Annual Meeting Showing That Most Fertility Patients Would Benefit From Moving More Rapidly to IVF Treatment

NEW YORK, NY--(Marketwired - Oct 22, 2014) - Celmatix, a privately held personalized medicine company focused on maximizing lifelong fertility, today presented a study titled Most Patients Would Benefit from Moving More Quickly to IVF: Results from a Cost-Effectiveness Analysis of a Large Retrospective Cohort at the 2014 Annual Meeting of the American Society for Reproductive Medicine (ASRM).

The study evaluated a decade of retrospective data from more than 60,000 treatment cycles corresponding to over 20,000 patients from a large reproductive medical center in the United States. The analysis showed that the most cost effective strategy for over 90% of fertility patients to achieve a viable pregnancy, while minimizing the risk of multiples, would be to either go straight to elective single embryo transfer in vitro fertilization (eSET IVF) treatment or progress quickly to eSET IVF after no more than 3 failed rounds of non-IVF fertility treatment. The study also found that most people do not follow the most cost effective strategies, potentially due to insurance providers limiting coverage to non-IVF fertility treatments or requiring that patients first fail these procedures before progressing to IVF.

"Currently, as many as one in four women discontinue fertility treatment while they still have a good chance of having a baby," said Dr. Piraye Yurttas Beim, Founder and CEO, of Celmatix. "Many of these women feel discouraged by multiple rounds of failed treatments, often required before their insurance providers will cover IVF. Our work demonstrates that initiating with or progressing quickly to eSET IVF is a win-win for both patients and payers. By avoiding unnecessary procedures and following a more personalized treatment plan, we believe patients are more likely to continue treatment and find success. Celmatix is working to identify the best treatment options for an individual, and eliminate strategies that aren't likely to work."

In total, Celmatix presented three studies at this year's ASRM:

  • Obesity has a Greater Impact on IVF Success Rates in Patients with PCOS
  • Most Patients Would Benefit from Moving More Quickly to IVF: Results from a Cost-Effectiveness Analysis of a Large Retrospective Cohort
  • Using Big Data Approaches to Refine the Gene Expression Signature of Endometriosis

About Celmatix, Inc.
Founded in 2009, Celmatix is a New York City-based personalized medicine company focused on maximizing lifelong fertility. By leveraging innovations in genomics, data science, and information technology, Celmatix is creating products that help personalize the treatment for infertility and fertility planning. Celmatix's key research discoveries include powerful predictive models that can calculate personalized chances for success for different treatment options across multiple cycles and the identification of Fertilome™DNA, the regions of the human genome that are most likely to influence a woman's fertility potential. For more information, visit www.celmatix.com.

Contact Information

  • Media Contact:
    Nicole Kruse
    EVC Group
    212-850-6025
    Email Contact